RxDoctor Payments Data

Otto Liao, MD

Allergy & Immunology · Tustin, CANPI 1225042674

Payments from drug & device makers

$15,693in general payments, 2019–2025

Across 717 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Pfizer$1K
  • CSL Behring$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • AstraZeneca$1K
  • plus $7K from 37 others

What the payments were for

  • Consulting fees$380%
  • Speaking & faculty fees$2001%
  • Food & beverage$15,22997%
  • Education$2261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,693 in reported general payments places this provider in the 80th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$179,636
Medicare patients
232
Services billed
11,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo13$679,773
Dupixent SyringeDupilumab41$175,325
XolairOmalizumab49$144,150
Dupixent PenDupilumab27$102,660
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$94,524
IcatibantIcatibant Acetate13$52,093
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$34,470
Breo ElliptaFluticasone/Vilanterol32$24,018
Advair HfaFluticasone Propion/Salmeterol12$8,566
Arnuity ElliptaFluticasone Furoate23$7,953
Ipratropium Bromide120$6,213
Wixela InhubFluticasone Propion/Salmeterol13$4,258
Azelastine Hcl47$2,694
Levocetirizine Dihydrochloride60$2,087
Fluticasone Propionate83$2,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Gammagard Liquid$1,597$774,29730 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,113$66,44081 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →